Variation in the cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) gene plays a significant role in determining susceptibility to autoimmune thyroid disease and type 1 diabetes. Its role in multiple sclerosis is more controversial. In order to explore this logical candidate more thoroughly, we genotyped 771 multiple sclerosis trio families from the United Kingdom for the 3V untranslated region variable number tandem repeat, the CT60 single nucleotide polymorphism (SNP) and five haplotype-tagging SNPs. No individual marker or common haplotype showed evidence of association with disease. These data suggest that any effect of CTLA-4 on multiple sclerosis susceptibility is likely to be very small. D
Introduction
Variation in the cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) gene plays a significant role in determining susceptibility to autoimmune thyroid disease and type 1 diabetes (Ueda et al., 2003) . In multiple sclerosis, its influence on disease susceptibility (Ligers et al., 1999; Fukazawa et al., 1999; Harbo et al., 1999; Rasmussen et al., 2001; Dyment et al., 2002; Maurer et al., 2002; Kantarci et al., 2003; van Veen et al., 2003; Alizadeh et al., 2003; Teutsch et al., 2004) and course (Masterman et al., 2002; Maurer et al., 2002) has been studied in a variety of populations. A trend towards association with the common short (8 repeat) allele of the variable number tandem repeat (VNTR) polymorphism in the 3V untranslated region (3VUTR) of the gene has been reported (Kantarci et al., 2003) . In nine other case control studies (Teutsch et al., 2004) , no consistent results have emerged. We systematically studied the gene in a large cohort of multiple sclerosis trio families (an affected individual and both parents). We studied the 3VUTR VNTR, and six single nucleotide polymorphisms (SNPs): CT60, which was identified by Ueda et al. (2003) as showing the strongest linkage disequilibrium with type 1 diabetes and thyroid disease, and five haplotype tagging SNPs (htSNPs) (T-1722C, A-1661G, C-658T, C-319T and A49G) described by Johnson et al. (2001) (see Fig. 1 ).
Patients and methods

Patients
The 771 patients included in this study were recruited throughout the UK. All patients satisfied the Poser criteria (Poser et al., 1983) for definite (95%), or probable (5%) multiple sclerosis; 60% had relapsing, 31% secondary progressive and 9% primary progressive multiple sclerosis. The mean age at diagnosis was 30.9 years; female to male ratio was 3.0:1. All patients and their parents gave written informed consent.
